+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Apellis Pharmaceuticals - logo

Apellis Pharmaceutical was founded in 2009 in Crestwood, U.S.A. It is a company with the aim of innovating and creating products to treat autoimmune and inflammatory diseases. Our lead compounds are designed to broadly inhibit complement C3, which is the central protein in the complement system.The complement system plays a key role in a wide range of autoimmune and inflammatory diseases. They believe with the use of C3 inhibition it may correct the immunological dysfunction. The approach they apply to this process is known as complement immunotherapy.

Complement C3 inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Complement C3 inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
EMPAVELI/ASPAVELI Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

EMPAVELI/ASPAVELI Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • September 2022
  • 30 Pages
  • Global
From
Stroke - Pipeline Review, H2 2020 - Product Thumbnail Image

Stroke - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 773 Pages
  • Global
From
Apellis Pharmaceuticals (APLS:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry - Product Thumbnail Image

Apellis Pharmaceuticals (APLS:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry

  • Company Profile
  • May 2023
  • 89 Pages
From
Comprehensive Report on Apellis Pharmaceuticals Inc, including SWOT, PESTLE and Business Model Canvas - Product Thumbnail Image

Comprehensive Report on Apellis Pharmaceuticals Inc, including SWOT, PESTLE and Business Model Canvas

  • SWOT Analysis
  • August 2023
  • 90 Pages
From
Loading Indicator